RIO DE JANEIRO, BRAZIL - Moderna Pharmaceuticals announced on May 25 that its Covid-19 vaccine is safe and effective for adolescents between the ages of 12 and 17, making it the second vaccine approved in the U.S. for this age group.
Moderna announced Tuesday that it will submit the results of its clinical study to the U.S. Food and Drug Administration (FDA) in early June for approval of its use with this age group.
The study, carried out on 3,700 adolescents in the United States, reveals the same effectiveness against the disease as among adults, with 93 . . .